EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease

Tama Dinur, Peter Bauer iD, Sabine Schroeder iD, Guido Kramp, Christian Beetz iD, Michal Becker-Cohen iD, Majdolen Istaiti iD, Dafna Frydman iD, Elena Shulman iD, Ari Zimran iD, Shoshana Revel-Vilk iD

International Journal of Molecular Sciences · 22.04.2026 · 27 (9) · 3726

DOI: 10.3390/ijms27093726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.04.2026. Verfasst von Tama Dinur und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel. Hauptthemen laut MEDLINE: Gaucher Disease, Psychosine. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucosylsphingosine (lyso-Gb1) serves as a biomarker for evaluating disease activity in Gaucher disease (GD). While treatment-related changes are documented, the dynamics of lyso-Gb1 during untreated states remain poorly understood. This retrospective, longitudinal cohort study utilized a large GD database comprising 701 patients and over 6200 visits with lyso-Gb1 measurements. Patients with at least two untreated visits were included in the analysis (n = 272). A significant change was defined as ≥50 ng/mL for lyso-Gb1, ≥1 g/dL for hemoglobin, and ≥50 × 109/L for platelet count. Multivariable logistic regression analyses identified clinical factors associated with lyso-Gb1 decline or an increase. During untreated states, 35 patients (12.9%; 95% CI 9.4–17.5%) exhibited a decline in lyso-Gb1, with a median decrease of 96.3 ng/mL. This decline was more common in females (OR 3.50, p = 0.032) and associated with higher initial lyso-Gb1 levels (p < 0.001) and baseline hemoglobin (p = 0.032). An increase in lyso-Gb1 was observed in 98 patients (36.0%; 95% CI 30.5–41.9%), with a median rise of 135.1 ng/mL. This increase correlated with lower baseline platelet counts (p = 0.003), lower baseline hemoglobin (p = 0.002), and longer follow-up duration (p = 0.001). In many cases, lyso-Gb1 increases were observed without a preceding change in hemoglobin or platelet count. In summary, declines in lyso-Gb1 in untreated states are rare but possible. The association with female sex may reflect inflammatory effects. Although increases in lyso-Gb1 were expected without treatment, they occurred mainly in patients with higher disease severity markers. Nevertheless, most patients in the untreated states remained stable within ±50 ng/mL. These findings demonstrate a heterogeneous trajectory of lyso-Gb1 across untreated states and highlight the importance of interpreting lyso-Gb1 changes within the clinical context when making treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseasePsychosineHumansFemaleBiomarkersMaleAdultRetrospective StudiesMiddle AgedLongitudinal StudiesPlatelet Count

Stichwörter der Autor:innen

Gaucher diseaseenzyme replacement therapy (ERT)glucosylsphingosinelyso-Gb1substrate reduction therapy (SRT)

Substanzen

Psychosinesphingosyl beta-glucosideBiomarkers

Autor:innen und Institutionen

  • Gaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
  • Centogene GmbH, 18055 Rostock, Germany.
  • Agyany Pharma Ltd., Jerusalem 9695614, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112002, Israel.

ORCID-Profile: Peter Bauer, Sabine Schroeder, Christian Beetz, Michal Becker-Cohen, Majdolen Istaiti, Dafna Frydman, Elena Shulman, Ari Zimran, Shoshana Revel-Vilk

Zitieren

APA

Dinur, T., Bauer, P., Schroeder, S., Kramp, G., Beetz, C., Becker-Cohen, M., Istaiti, M., Frydman, D., Shulman, E., Zimran, A., & Revel-Vilk, S. (2026). Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease. International Journal of Molecular Sciences, 27(9), 3726. https://doi.org/10.3390/ijms27093726

Vancouver

Dinur T, Bauer P, Schroeder S, Kramp G, Beetz C, Becker-Cohen M, et al. Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease. International Journal of Molecular Sciences. 2026;27(9):3726. doi:10.3390/ijms27093726

BibTeX
@article{Dinur2026,
  author = {Dinur, Tama and Bauer, Peter and Schroeder, Sabine and Kramp, Guido and Beetz, Christian and Becker-Cohen, Michal and Istaiti, Majdolen and Frydman, Dafna and Shulman, Elena and Zimran, Ari and Revel-Vilk, Shoshana},
  title = {Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {3726},
  doi = {10.3390/ijms27093726}
}
Kostenlos starten →